NDLI: Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma

Content Provider	PubMed Central
Author	Villa, Antonio Mazzola, Anna Alice Ghio, Stefano Martinoli, Elena Marino, Pietro
Copyright Year	2011
Abstract	Multiple myeloma (MM) is thrombogenic as a consequence of multiple hemostatic effects. Thalidomide is an effective treatment; however, it has been associated with an increased risk of thromboembolic events including pulmonary hypertension (PH). PH in the absence of thromboembolic events has also been described in some patients with MM during thalidomide treatment. We experienced occurrence of PH in a MM patient during treatment with thalidomide. A 79-year-old woman was diagnosed with IgG lambda MM and was started on thalidomide treatment. About a month later, she presented with asthenia, palpitation and dyspnoea on exertion and was hospitalized. An echocardiography revealed severe PH (systolic pulmonary artery pressure 75 mm Hg) without paradoxic movement of ventricular septum or right ventricular dysfunction signs; a previous echocardiography was normal. Pulmonary computed tomography and perfusion scan were negative for pulmonary embolism. Based on the hypothesis of a pharmacological pathogenesis, thalidomide was promptly interrupted. About a month later, she was hospitalized for further investigations. Physical examination documented absence of dyspnoea or other respiratory signs, and echocardiography showed normal right ventricular function and normal pulmonary artery pressure. As in the cases reported in the literature, we suggest a possible direct correlation between thalidomide and PH, since in all cases a rapid decrease of pulmonary artery pressure after thalidomide discontinuation was observed.
Related Links	http://dx.doi.org/10.1159/000333016
Ending Page	489
Page Count	3
Starting Page	487
File Format	PDF
ISSN	16626575
e-ISSN	16626575
Journal	Case Reports in Oncology
Issue Number	3
Volume Number	4
Language	English
Publisher	S. Karger AG
Publisher Date	2011-01-01
Access Restriction	Open
Rights Holder	S. Karger AG
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Pulmonary Hypertension Induced by Thalidomide (and Derivatives) in Patients with Multiple Myeloma: A Systematic Review

Thalidomide and its analogues in the treatment of Multiple Myeloma

Access to thalidomide for the treatment of multiple myeloma in Canada: physician behaviours and ethical implications

Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature

Thalidomide and its analogues in the treatment of Multiple Myeloma

Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis

Elotuzumab for the treatment of multiple myeloma

Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma

Similar Documents

Pulmonary Hypertension Induced by Thalidomide (and Derivatives) in Patients with Multiple Myeloma: A Systematic Review

Thalidomide and its analogues in the treatment of Multiple Myeloma

Access to thalidomide for the treatment of multiple myeloma in Canada: physician behaviours and ethical implications

Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature

Thalidomide and its analogues in the treatment of Multiple Myeloma

Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis

Elotuzumab for the treatment of multiple myeloma

Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma